RESUMO
BACKGROUND/PURPOSE: Andersen-Tawil syndrome type 1 is a rare autosomal dominant disease caused by a KCNJ2 gene mutation and clinically characterized by dysmorphic features, periodic muscular paralysis, and frequent ventricular arrhythmias (VAs). Although polymorphic and bidirectional ventricular tachycardias are prevalent, PVCs are the most frequent VAs. In addition, a "dominant" morphology with RBBB pattern associated with either superior or inferior axis is seen in most of the patients. Due to the limited efficacy of most antiarrhythmic drugs, catheter ablation (CA) is an alternative in patients with monomorphic VAs. Based on our experience, we aimed to review the arrhythmogenic mechanisms and substrates for VAs, and we analyzed the potential reasons for CA failure in this group of patients. METHODS: Case report and focused literature review. RESULTS: Catheter ablation has been reported to be unsuccessful in all of the few cases published so far. Most of the information suggests that VAs are mainly originated from the left ventricle and probably in the Purkinje network. Although identifying well-established and accepted mapping criteria for successful ablation of a monomorphic ventricular arrhythmia, papillary muscles seem not to be the right target. CONCLUSIONS: More research is needed to understand better the precise mechanism and site of origin of VAs in Andersen-Tawil syndrome patients with this particular "dominant" monomorphic ventricular pattern to establish the potential role of CA.
Assuntos
Síndrome de Andersen , Ablação por Cateter , Taquicardia Ventricular , Complexos Ventriculares Prematuros , Humanos , Síndrome de Andersen/genética , Síndrome de Andersen/cirurgia , Síndrome de Andersen/complicações , Ventrículos do Coração/cirurgia , Complexos Ventriculares Prematuros/cirurgia , Ablação por Cateter/efeitos adversosRESUMO
Bidirectional ventricular tachycardia (VT) is a rare ventricular dysrhythmia with a limited differential diagnosis that includes digitalis toxicity, catecholaminergic polymorphic VT, aconite poisoning, and genetic channelopathy syndromes, specifically, Andersen-Tawil syndrome (ATS). We present a case of a young female with palpitations found to have bidirectional VT on cardiac event monitor and strong family history of cardiac dysrhythmias. Her physical examination findings included minor dysmorphic features of mandibular hypoplasia, hypertelorism, and clinodactyly. The patient was clinically diagnosed with ATS and started on a beta-blocker for control of ectopy. A second Holter review demonstrated markedly decreased burden of ventricular ectopy compared to the initial monitoring. She was referred for genetic testing, which revealed a KCNJ2 mutation. Bidirectional VT is an uncommon ventricular dysrhythmia that has a limited differential diagnosis, one of which is ATS-a rare genetic disorder that results from mutations in the KCNJ2 gene. The condition is frequently associated with developmental, skeletal, and cardiac abnormalities. Although there are no strong recommendations that exist for treatment of ventricular dysrhythmias associated with this genetic disorder, we demonstrate a case of clinical improvement in a patient with ATS by using the beta-blocker metoprolol succinate. Furthermore, we propose that ATS patients may not need exercise restrictions as overall ventricular ectopy burden decreased with exercise and there was no prolongation of the QT interval. This patient will continue to follow up in our clinic to reassess symptom burden and for continued monitoring for the development of any new features.
Assuntos
Síndrome de Andersen , Taquicardia Ventricular , Complexos Ventriculares Prematuros , Humanos , Feminino , Síndrome de Andersen/complicações , Síndrome de Andersen/diagnóstico , Síndrome de Andersen/genética , Complexos Ventriculares Prematuros/complicações , Complexos Ventriculares Prematuros/genética , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/tratamento farmacológico , Testes GenéticosRESUMO
Bidirectional ventricular tachycardia (BiVT) is a rare form of ventricular tachycardia that manifests on surface electrocardiogram by dual QRS morphologies alternating on a beat-to-beat basis. It was first reported in the 1920s as a complication of digoxin, and since then, it has been reported in other conditions including fulminant myocarditis, sarcoidosis, catecholaminergic polymorphic ventricular tachycardia, and Andersen-Tawil syndrome. The mechanism for BiVT is not as well known as other forms of ventricular tachycardia but appears to include typical mechanisms including triggered activity from afterdepolarizations, abnormal automaticity, or reentry. This review will go beyond the definition, surface electrocardiogram, mechanisms, causes, and treatment of BiVT as per our current understanding.
Assuntos
Síndrome de Andersen , Taquicardia Ventricular , Síndrome de Andersen/complicações , Eletrocardiografia/efeitos adversos , Humanos , Taquicardia , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/terapiaRESUMO
Andersen-Tawil syndrome is a rare autosomal dominant genetic or sporadic disorder characterized by periodic paralysis, ventricular arrhythmias and dysmorphic features. Ventricular arrhythmias can include frequent premature ventricular complex, polymorphic ventricular tachycardia, and less frequently bidirectional ventricular tachycardia. Left ventricle function has been reported in only a few individual cases of Andersen-Tawil syndrome. A 14-year-old female patient was referred to our clinic from another center with documented arrhythmia and left ventricular systolic dysfunction. Andersen-Tawil syndrome was suspected and the diagnosis was confirmed after detection of a previously unreported mutation in children. We report the successful use of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy in a case of Andersen-Tawil syndrome associated with a novel mutation.
Assuntos
Síndrome de Andersen , Cardiomiopatias , Taquicardia Ventricular , Adolescente , Síndrome de Andersen/complicações , Síndrome de Andersen/tratamento farmacológico , Síndrome de Andersen/genética , Cardiomiopatias/complicações , Cardiomiopatias/tratamento farmacológico , Criança , Feminino , Flecainida/uso terapêutico , Humanos , Taquicardia , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/genéticaRESUMO
Andersen-Tawil syndrome (ATS) is a rare autosomal dominant neuromuscular disorder due to mutations in the KCNJ2 gene. The classical phenotype of ATS consists of a triad of periodic paralysis, cardiac conduction abnormalities and dysmorphic features. Episodes of either muscle weakness or cardiac arrhythmia may predominate however, and dysmorphic features may be subtle, masking the true breadth of the clinical presentation, and posing a diagnostic challenge. The severity of cardiac involvement varies but includes reports of life-threatening events or sudden cardiac death, usually attributed to ventricular tachyarrhythmias. We report the first case of advanced atrioventricular (AV) block in ATS and highlight clinical factors that may delay diagnosis.
Assuntos
Síndrome de Andersen/complicações , Bloqueio Atrioventricular/etiologia , Síndrome de Andersen/diagnóstico , Síndrome de Andersen/fisiopatologia , Bloqueio Atrioventricular/diagnóstico , Bloqueio Atrioventricular/fisiopatologia , Diagnóstico Tardio , HumanosRESUMO
A 25-year-old male patient presented with periodic paralysis that increased in severity and frequency with age, accompanied with muscle pain and significantly elevated creatine kinase (CK) levels. Initial clinical and genetic examination confirmed Andersen-Tawil syndrome. Although his father carried the same genetic mutation (p.G300A), he experienced minor and infrequent attacks of paralysis. A change in the patient's symptoms, such as accompanying pain, contracture, and significant CK elevation, lead to a reconsideration of the diagnosis. A muscle biopsy of the biceps brachii in the patient revealed glycogen storage, but no tubular aggregates. Analysis of the phosphorylase kinase regulatory subunit alpha 1 (PHKA1) gene revealed a pathogenic mutation (p.C1082X), indicating glycogen storage disease type â ¨d. The case demonstrates that co-occurrence of glycogen storage disease type â ¨d may prolong attacks of muscle weakness, and cause serious muscle pain in patients with Andersen-Tawil syndrome.
Assuntos
Síndrome de Andersen/diagnóstico , Doenças Genéticas Ligadas ao Cromossomo X/diagnóstico , Doença de Depósito de Glicogênio/diagnóstico , Debilidade Muscular/etiologia , Adulto , Síndrome de Andersen/complicações , Doenças Genéticas Ligadas ao Cromossomo X/complicações , Doença de Depósito de Glicogênio/complicações , Humanos , Masculino , MutaçãoRESUMO
BACKGROUND: Andersen-Tawil Syndrome type 1 (ATS1) is a rare arrhythmogenic disorder, caused by loss-of-function mutations in the KCNJ2 gene. We present here the largest cohort of patients with ATS1 with outcome data reported. OBJECTIVES: This study sought to define the risk of life-threatening arrhythmic events (LAE), identify predictors of such events, and define the efficacy of antiarrhythmic therapy in patients with ATS1. METHODS: Clinical and genetic data from consecutive patients with ATS1 from 23 centers were entered in a database implemented at ICS Maugeri in Pavia, Italy, and pooled for analysis. RESULTS: We enrolled 118 patients with ATS1 from 57 families (age 23 ± 17 years at enrollment). Over a median follow-up of 6.2 years (interquartile range: 2.7 to 16.5 years), 17 patients experienced a first LAE, with a cumulative probability of 7.9% at 5 years. An increased risk of LAE was associated with a history of syncope (hazard ratio [HR]: 4.54; p = 0.02), with the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) and with the administration of amiodarone (HR: 268; p < 0.001). The rate of LAE without therapy (1.24 per 100 person-years [py]) was not reduced by beta-blockers alone (1.37 per 100 py; p = 1.00), or in combination with Class Ic antiarrhythmic drugs (1.46 per 100 py, p = 1.00). CONCLUSIONS: Our data demonstrate that the clinical course of patients with ATS1 is characterized by a high rate of LAE. A history of unexplained syncope or of documented sustained ventricular tachycardia is associated with a higher risk of LAE. Amiodarone is proarrhythmic and should be avoided in patients with ATS1.
Assuntos
Síndrome de Andersen/complicações , Arritmias Cardíacas/etiologia , Medição de Risco , Adolescente , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Amiodarona/administração & dosagem , Amiodarona/efeitos adversos , Síndrome de Andersen/genética , Síndrome de Andersen/terapia , Antiarrítmicos/administração & dosagem , Antiarrítmicos/efeitos adversos , Arritmias Cardíacas/terapia , Criança , Pré-Escolar , Bases de Dados Factuais , Morte Súbita Cardíaca/epidemiologia , Desfibriladores Implantáveis , Eletrocardiografia , Feminino , Testes Genéticos , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/etiologia , Mutação , Canais de Potássio Corretores do Fluxo de Internalização/genética , Síncope/etiologia , Síncope/terapia , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/terapia , Adulto JovemRESUMO
Andersen-Tawil Syndrome (ATS) is a rare periodic paralysis with typical skeletal and neuromuscular features. Cardiac involvement may range from asymptomatic ventricular arrhythmias to sudden death. Its management remains challenging and the choice between antiarrhythmic drug therapy and implantable cardioverter defibrillator (ICD) is not simple. We present a case of ATS patient with episodes of bidirectional ventricular tachycardia, well controlled by flecainide therapy initially, which in particular conditions of fever and hypokaliemia had a cardiac arrest with ventricular fibrillation, with neurological sequelae and need of an ICD implant. A review of the therapeutic management of this disease is presented.
Assuntos
Síndrome de Andersen , Desfibriladores Implantáveis , Taquicardia Ventricular , Síndrome de Andersen/complicações , Síndrome de Andersen/diagnóstico , Síndrome de Andersen/terapia , Antiarrítmicos/uso terapêutico , Morte Súbita Cardíaca/prevenção & controle , Eletrocardiografia , Flecainida , Humanos , Taquicardia Ventricular/tratamento farmacológico , Taquicardia Ventricular/terapiaRESUMO
Andersen-Tawil syndrome (ATS) is an inherited disorder characterised by the triad of ventricular arrhythmias (VAs), periodic paralysis and dysmorphic features. A 31-year-old woman diagnosed with ATS caused by a KCNJ2 mutation (p.R228ins) was urgently admitted to our hospital following an episode of syncope during exercise. Electrocardiography revealed frequent premature ventricular complexes and non-sustained ventricular tachycardias (VTs) with pleomorphic QRS patterns. During the intravenous flecainide test (30 mg), the frequent VAs were inhibited completely. After oral flecainide (100 mg) was started, VAs, except for a brief bigeminy, were suppressed during the exercise test. On 24-hour Holter recordings, the VAs decreased from 50 133 to 13 363 beats/day (-73%). Sustained VT and syncope were not observed during a 3-year follow-up period. Intravenous flecainide challenge test may be useful in predicting the efficacy of oral flecainide treatment for patients with ATS.
Assuntos
Síndrome de Andersen/complicações , Antiarrítmicos/administração & dosagem , Flecainida/administração & dosagem , Complexos Ventriculares Prematuros/etiologia , Administração Intravenosa , Administração Oral , Adulto , Síndrome de Andersen/tratamento farmacológico , Síndrome de Andersen/genética , Síndrome de Andersen/fisiopatologia , Antiarrítmicos/uso terapêutico , Eletrocardiografia , Feminino , Flecainida/uso terapêutico , Humanos , Síncope/etiologia , Síncope/fisiopatologia , Usos Terapêuticos , Resultado do Tratamento , Complexos Ventriculares Prematuros/tratamento farmacológico , Complexos Ventriculares Prematuros/fisiopatologiaRESUMO
We report on a 44-year-old woman with coincidence of two genetic disorders: Andersen-Tawil syndrome and Marfan syndrome. In both, life-threatening arrhythmias could occur. A 44-year-old woman presented acute ascending aortic dissection with aortic arch involvement and chronic thoracic descending and abdominal aortic dissection. Clinical and genetic examination confirmed Marfan syndrome (MFS) diagnosis. Due to repolarization disorder in ECG and premature ventricular contractions in Holter ECG, the sequencing data were analyzed again and mutation in KCNJ2 gene was identified. The case showed that coincidence of Andersen-Tawil syndrome (ATS) and MFS did not provoke life-threatening arrhythmias. Complication was rather caused by expression of FBN1 mutation.
Assuntos
Síndrome de Andersen/genética , Fibrilina-1/genética , Predisposição Genética para Doença , Síndrome de Marfan/genética , Canais de Potássio Corretores do Fluxo de Internalização/genética , Adulto , Síndrome de Andersen/complicações , Síndrome de Andersen/diagnóstico , Dissecção Aórtica/diagnóstico , Dissecção Aórtica/etiologia , Dissecção Aórtica/cirurgia , Aneurisma da Aorta Torácica/diagnóstico , Aneurisma da Aorta Torácica/etiologia , Aneurisma da Aorta Torácica/cirurgia , Eletrocardiografia , Serviço Hospitalar de Emergência , Feminino , Canais de Potássio Corretores do Fluxo de Internalização Acoplados a Proteínas G/genética , Humanos , Síndrome de Marfan/complicações , Síndrome de Marfan/diagnóstico , Monitorização Fisiológica , Multimorbidade , Mutação , Doenças Raras , Medição de Risco , Índice de Gravidade de Doença , Resultado do TratamentoAssuntos
Síndrome de Andersen/complicações , Síndrome de Andersen/fisiopatologia , Debilidade Muscular/etiologia , Debilidade Muscular/fisiopatologia , Síndrome de Andersen/diagnóstico , Síndrome de Andersen/genética , Antiarrítmicos/uso terapêutico , Criança , Feminino , Humanos , Debilidade Muscular/tratamento farmacológico , Canais de Potássio Corretores do Fluxo de Internalização/genética , Síncope , Complexos Ventriculares PrematurosRESUMO
BACKGROUND: Andersen-Tawil syndrome (ATS) is a rare familial periodic paralysis that typically also affects the heart and skeletal system. Ventricular arrhythmias (VAs) are profound and difficult to control, but minimally symptomatic. In this report, we describe an atypical phenotype of ATS in two related families. We also report our experience with phenytoin sodium for the control of resistant VAs in these patients. METHODS AND RESULTS: Between 2014 and 2018, seven siblings were diagnosed with ATS on the basis of cardiac arrhythmias and genetic evaluation. Heterozygous mutation with c.431G > C (p.G144A) in exon 2 of KCNJ2 gene was observed in all patients. Characteristic cardiac manifestations were noted in all patients but periodic paralysis or objective neurological involvement was distinctly absent. Phenytoin was considered for control of symptomatic VA in three patients. Intake of oral phenytoin (5 mg/kg/day) for 1 month completely suppressed VA (<1% in 24-h Holter monitoring) in two patients, and significantly in the third (8% per 24 h) patient. Phenytoin was well-tolerated in all three patients. CONCLUSIONS: We describe a cardiac-predominant phenotype in ATS. ATS should be suspected in patients with typical cardiac manifestations even in the absence of periodic paralysis. Our initial experience with short-term use of phenytoin for control of resistant VAs is encouraging.
Assuntos
Síndrome de Andersen/complicações , Arritmias Cardíacas/tratamento farmacológico , Arritmias Cardíacas/etiologia , Fenitoína/uso terapêutico , Adolescente , Adulto , Algoritmos , Síndrome de Andersen/genética , Feminino , Humanos , Masculino , Linhagem , Fenótipo , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
Andersen-Tawil syndrome (ATS) is a disorder that causes episodes of muscle weakness (periodic paralysis), changes in heart rhythm, and developmental abnormalities. QT prolongation and ventricular arrhythmias, including bidirectional ventricular tachycardia (VT) and polymorphic VT, may occur. About 60% of all cases of the disorder arecaused by mutations in the KCNJ2 gene. A 13-year-old female patient was referred for frequent premature ventricular contractions. Suspicion of ATS due to dysmorphic findings, electrocardiogram changes, and periodic muscle weakness was genetically confirmed. Beta-blocker therapy was initiated as a first-line treatment for bidirectional VT and frequent polymorphic premature ventricular contractions. Despite proper treatment, the VT attacks were not brought under control. Flecainide was added to the treatment regime. The number of premature ventricular contractions was dramatically reduced with flecainide and the VT attacks completely disappeared. This patient is a rare example of ATS in our country. This article provides a description of successful management of rhythm disturbance in a patient with ATS.
Assuntos
Síndrome de Andersen , Antiarrítmicos/uso terapêutico , Flecainida/uso terapêutico , Taquicardia Ventricular , Adolescente , Síndrome de Andersen/complicações , Síndrome de Andersen/tratamento farmacológico , Criança , Feminino , Humanos , Taquicardia Ventricular/tratamento farmacológico , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/prevenção & controleAssuntos
Síndrome de Andersen/fisiopatologia , Debilidade Muscular/fisiopatologia , Adolescente , Idade de Início , Síndrome de Andersen/complicações , Síndrome de Andersen/genética , Criança , Humanos , Masculino , Debilidade Muscular/etiologia , Debilidade Muscular/genética , Canais de Potássio Corretores do Fluxo de Internalização/genéticaRESUMO
Andersen-Tawil syndrome is a rare autosomal dominant disease characterized by the clinical triad of periodic paralysis, long QT with ventricular arrhythmias, and dysmorphic facial or skeletal features. However, the phenotypic heterogeneity and poor disease awareness of this syndrome can hinder an accurate and timely diagnosis. In this study, we describe a Korean family with Andersen-Tawil syndrome with a G215D mutation of the KCNJ2 gene revealed by diagnostic exome sequencing. Two sisters had severe growth restriction, characteristic facial anomalies, and developmental delay. The father carried the same mutation with similar characteristic facial features and short stature. This family lacked periodic paralysis. This report highlights the importance of an exome study for unusual clinical manifestations, such as preand postnatal growth restriction, developmental delay, and the lack of a critical diagnostic clue, such as periodic paralysis.
Assuntos
Síndrome de Andersen/complicações , Síndrome de Andersen/genética , Povo Asiático/genética , Deficiências do Desenvolvimento/complicações , Deficiências do Desenvolvimento/genética , Mutação/genética , Canais de Potássio Corretores do Fluxo de Internalização/genética , Adulto , Sequência de Bases , Análise Mutacional de DNA , Família , Feminino , Humanos , Lactente , Masculino , Dados de Sequência Molecular , Linhagem , GravidezAssuntos
Síndrome de Andersen/complicações , Morte Súbita Cardíaca/etiologia , Eletroencefalografia , Epilepsia/complicações , Cardiopatias Congênitas/complicações , Síndrome de Andersen/fisiopatologia , Criança , Ecocardiografia , Epilepsia/fisiopatologia , Feminino , Cardiopatias Congênitas/fisiopatologia , HumanosRESUMO
INTRODUCTION: Andersen-Tawil syndrome (ATS) is a potassium channelopathy affecting cardiac and skeletal muscle. Periodic paralysis is a presenting symptom in some patients, whereas, in others, symptomatic arrhythmias or prolongation of QT in echocardiographic recordings will lead to diagnosis of ATS. Striking intrafamilial variability of expression of KCNJ2 mutations and rarity of the syndrome may lead to misdiagnosis. METHODS: We report 15 patients from 8 Polish families with ATS, including 3 with novel KCNJ2 mutations. RESULTS: All patients had dysmorphic features; periodic paralysis affected males more frequently than females (80% vs. 20%), and most attacks were normokalemic. Two patients (with T75M and T309I mutations) had aborted sudden cardiac death. An implantable cardioverter-defibrillator was utilized in 40% of cases. CONCLUSIONS: KCNJ2 mutations cause a variable phenotype, with dysmorphic features seen in all patients studied, a high penetrance of periodic paralysis in males and ventricular arrhythmia with a risk of sudden cardiac death.
Assuntos
Síndrome de Andersen/complicações , Síndrome de Andersen/genética , Predisposição Genética para Doença/genética , Cardiopatias/etiologia , Mutação/genética , Canais de Potássio Corretores do Fluxo de Internalização/genética , Adolescente , Adulto , Síndrome de Andersen/cirurgia , Criança , Análise Mutacional de DNA , Desfibriladores Implantáveis , Ecocardiografia , Feminino , Cardiopatias/genética , Cardiopatias/cirurgia , Humanos , Estudos Longitudinais , Masculino , Paralisias Periódicas Familiares/etiologia , Paralisias Periódicas Familiares/genética , Polônia , Estudos Retrospectivos , Adulto JovemRESUMO
BACKGROUND: Andersen-Tawil syndrome (ATS) is an autosomal dominant genetic or sporadic disorder characterized by ventricular arrhythmias (VAs), periodic paralyses, and dysmorphic features. The optimal pharmacological treatment of VAs in patients with ATS remains unknown. OBJECTIVE: We evaluated the efficacy and safety of flecainide for VAs in patients with ATS with KCNJ2 mutations. METHODS: Ten ATS probands (7 females; mean age 27 ± 11 years) were enrolled from 6 institutions. All of them had bidirectional VAs in spite of treatment with ß-blockers (n = 6), but none of them had either aborted cardiac arrest or family history of sudden cardiac death. Twenty-four-hour Holter recording and treadmill exercise test (TMT) were performed before (baseline) and after oral flecainide therapy (150 ± 46 mg/d). RESULTS: Twenty-four-hour Holter recordings demonstrated that oral flecainide treatment significantly reduced the total number of VAs (from 38,407 ± 19,956 to 11,196 ± 14,773 per day; P = .003) and the number of the longest ventricular salvos (23 ± 19 to 5 ± 5; P = .01). At baseline, TMT induced nonsustained ventricular tachycardia (n = 7) or couplets of premature ventricular complex (n = 2); treatment with flecainide completely (n = 7) or partially (n = 2) suppressed these exercise-induced VAs (P = .008). In contrast, the QRS duration, QT interval, and U-wave amplitude of the electrocardiogram were not altered by flecainide therapy. During a mean follow-up of 23 ± 11 months, no patients developed syncope or cardiac arrest after oral flecainide treatment. CONCLUSION: This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide.
Assuntos
Síndrome de Andersen/complicações , Antiarrítmicos/uso terapêutico , Eletrocardiografia Ambulatorial , Flecainida/uso terapêutico , Taquicardia Ventricular/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Síndrome de Andersen/genética , Síndrome de Andersen/fisiopatologia , Flecainida/administração & dosagem , Flecainida/efeitos adversos , Seguimentos , Parada Cardíaca/epidemiologia , Parada Cardíaca/prevenção & controle , Humanos , Canais de Potássio Corretores do Fluxo de Internalização/genética , Síncope/epidemiologia , Síncope/prevenção & controle , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/fisiopatologia , Resultado do Tratamento , Complexos Ventriculares Prematuros/tratamento farmacológico , Complexos Ventriculares Prematuros/epidemiologia , Complexos Ventriculares Prematuros/fisiopatologia , Adulto JovemRESUMO
El síndrome de Andersen-Tawil resulta de la alteración de canales de potasio, se hereda de forma autosómica dominante y se cataloga como el tipo 7 de los síndromes de QT largo congénitos. El gen afectado es el KCNJ2, el cual codifica la proteína Kir2.1 que forma el canal de potasio rectificador interno («inward rectifier¼). Este canal interviene en la estabilización del potencial de membrana en reposo y controla la duración del potencial de acción en el sistema musculoesquelético y cardíaco. En miocitos ventriculares, es un componente responsable de la rectificación de la corriente de potasio en la fase 3 del potencial de acción. Debido a que Kir2.1 está presente en el sistema musculoesquelético, corazón y cerebro, las alteraciones de esta proteína dan origen a las principales características del síndrome: parálisis flácida, arritmias ventriculares y alteraciones leves a moderadas en el desarrollo del esqueleto, especialmente en manos y pies. En la presente revisión se aborda esta enfermedad desde el punto de vista del diagnóstico clínico y molecular con énfasis en sus manifestaciones cardíacas.
The Andersen-Tawil syndrome is a cardiac ion channel disease that is inherited in an autosomal dominant way and is classified as type 7 of the congenital long QT syndromes. Affected gene is KCNJ2, which forms the inward rectifier potassium channel designated Kir2.1. This protein is involved in stabilizing the resting membrane potential and controls the duration of the action potential in skeletal muscle and heart. It also participates in the terminal repolarization phase of the action potential in ventricular myocytes and is a major component responsible for the correction in the potassium current during phase 3 of the action potential repolarization. Kir 2.1 channel has a predominant role in skeletal muscle, heart and brain. Alterations in this channel produce flaccid paralysis, arrhythmias, impaired skeletal development primarily in extremities and facial area. In this review we address the disease from the point of view of clinical and molecular diagnosis with emphasis on cardiac manifestations.